Bimagrumab
Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
Eli Lilly · Phase 2 · Recruiting · Enrollment 63
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Tirzepatide + bimagrumab | n/r | n/r | n/r | n/r |
| Tirzepatide + placebo | n/r | n/r | n/r | n/r |
| Bimagrumab + placebo | n/r | n/r | n/r | n/r |
Not shown
- Tirzepatide + bimagrumab: endpoint not reported
- Tirzepatide + placebo: endpoint not reported
- Bimagrumab + placebo: endpoint not reported